Literature DB >> 18194099

Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia.

Harish Jasti1, Eric M Mortensen, David Scott Obrosky, Wishwa N Kapoor, Michael J Fine.   

Abstract

BACKGROUND: Rehospitalization after inpatient treatment of community-acquired pneumonia occurs in one-tenth of all hospitalizations, but the clinical circumstances surrounding readmission to the hospital have not been well studied. The objective of this study was to identify the causes and risk factors for rehospitalization of inpatients with community-acquired pneumonia.
METHODS: This project was performed as part of a randomized, multicenter, controlled trial of the implementation of practice guidelines to reduce the duration of intravenous antibiotic therapy and duration of hospitalization for patients who have received a clinical and radiographic diagnosis of pneumonia. The trial was conducted at 7 hospitals in Pittsburgh, Pennsylvania, from February 1998 through March 1999. The primary outcome for these analyses was rehospitalization within 30 days after the index hospitalization. Two physicians independently assigned the cause of rehospitalization as pneumonia related, comorbidity related, or both; consensus was reached for all assignments. Patient demographic characteristics and clinical factors independently associated with rehospitalization were identified using multiple logistic regression analysis.
RESULTS: Of the 577 patients discharged after hospitalization for community-acquired pneumonia, 70 (12%) were rehospitalized within 30 days. The median time to rehospitalization was 8 days (interquartile range, 4-13 days). Overall, 52 rehospitalizations (74%) were comorbidity related, and 14 (20%) were pneumonia related. The most frequent comorbid conditions responsible for rehospitalization were cardiovascular (n = 19), pulmonary (n = 6) and neurological (n = 6) in origin. Less than a high school education (odds ratio, 2.0; 95% confidence interval, 1.1-3.4), unemployment (odds ratio, 3.7; 95% confidence interval, 1.1-12.3), coronary artery disease (odds ratio, 2.7; 95% confidence interval, 1.5-4.7), and chronic obstructive pulmonary disease (odds ratio, 2.3; 95% confidence interval, 1.3-4.1) were independently associated with rehospitalization.
CONCLUSIONS: The majority of rehospitalizations following pneumonia are comorbidity related and are the result of underlying cardiopulmonary and/or neurologic diseases. Careful attention to the clinical stability of patients with these coexisting conditions at and following hospital discharge may decrease the frequency of rehospitalization of patients with community-acquired pneumonia.

Entities:  

Mesh:

Year:  2008        PMID: 18194099     DOI: 10.1086/526526

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  49 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.

Authors:  Kenneth Berman; Sweta Tandra; Kate Forssell; Raj Vuppalanchi; Raj Vuppalanch; James R Burton; James Nguyen; Devonne Mullis; Paul Kwo; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-17       Impact factor: 11.382

3.  Effect of Posthospital Syndrome on Health Care Utilization After Abdominal Contouring Surgery.

Authors:  Peter R Swiatek; Shepard P Johnson; Lu Wang; Mochuan Liu; Ting-Ting Chung; Kevin C Chung
Journal:  Ann Plast Surg       Date:  2018-12       Impact factor: 1.539

4.  Hospital admissions for pneumonia more likely with concomitant dental infections.

Authors:  Brian Laurence; Nee-Kofi Mould-Millman; Frank A Scannapieco; Armin Abron
Journal:  Clin Oral Investig       Date:  2014-10-31       Impact factor: 3.573

5.  Healthcare reconsultation in working-age adults following hospitalisation for community-acquired pneumonia.

Authors:  Priya Daniel; Thomas Bewick; Tricia M McKeever; Mark Roberts; Deborah Ashton; Daniel Smith; Lenny Latip; Wei Shen Lim
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

Review 6.  Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review.

Authors:  Linda Calvillo-King; Danielle Arnold; Kathryn J Eubank; Matthew Lo; Pete Yunyongying; Heather Stieglitz; Ethan A Halm
Journal:  J Gen Intern Med       Date:  2012-10-06       Impact factor: 5.128

7.  Revolving-door patients in a public psychiatric hospital in Israel: cross sectional study.

Authors:  Igor Oyffe; Rena Kurs; Marc Gelkopf; Yuval Melamed; Avi Bleich
Journal:  Croat Med J       Date:  2009-12       Impact factor: 1.351

8.  Predictors of inhospital mortality and re-hospitalization in older adults with community-acquired pneumonia: a prospective cohort study.

Authors:  Binod Neupane; Stephen D Walter; Paul Krueger; Tom Marrie; Mark Loeb
Journal:  BMC Geriatr       Date:  2010-05-11       Impact factor: 3.921

9.  Influence of socioeconomic status on community-acquired pneumonia outcomes in elderly patients requiring hospitalization: a multicenter observational study.

Authors:  Conchita Izquierdo; Manuel Oviedo; Laura Ruiz; Xavier Sintes; Isabel Vera; Manel Nebot; Jose-María Bayas; Jordi Carratalà; Wenceslao Varona; Dolores Sousa; Jose-Miguel Celorrio; Luis Salleras; Angela Domínguez
Journal:  BMC Public Health       Date:  2010-07-15       Impact factor: 3.295

10.  Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure.

Authors:  Kumar Dharmarajan; Kelly M Strait; Mary E Tinetti; Tara Lagu; Peter K Lindenauer; Joanne Lynn; Michelle R Krukas; Frank R Ernst; Shu-Xia Li; Harlan M Krumholz
Journal:  J Am Geriatr Soc       Date:  2016-07-22       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.